Development of the alopecia areata symptom impact scale.
Development of the alopecia areata symptom impact scale.
复制标题
DOI：
10.1038/jidsymp.2013.19
复制
发表时间：
2013-12-01
期刊：
影响因子：
--
通讯作者：
Duvic, Madeleine
中科院分区：
文献类型：
--
作者：
Mendoza, Tito R;Osei, Joyce S;Duvic, Madeleine
现有关于斑秃(AA)的文献清楚地表明了患者对身体症状、情绪健康、心理健康、社交功能和其他日常功能方面的担忧。虽然已经使用了Skindex-16和皮肤病生活质量指数等问卷，但这些问卷是针对皮肤状况进行验证的，而不是将AA作为慢性病。这项研究的目标是开发一种测量AA患者的生活质量、症状及其影响的工具，称为斑秃症状影响量表(AASIS)，并为其使用提供心理测量学证据。我们使用了来自国家斑秃注册中心的1400名患者的数据，以及临床专家的评论和量化方法。AASIS初版包括13个条目，对大约210名再生障碍性贫血患者进行了测试。结果表明，AASIS测量了与AA相关的三个潜在结构。这些维度是AA、脱发和身体皮肤症状的影响。各分量表的内部一致性信度分别为0.93、0.86、0.81。认知情况汇报结果显示，患者认为AASIS项目易于理解、清晰和简洁。初步证据表明，AASIS是一种可靠和有效的衡量再生障碍性贫血患者症状及其影响的方法。
The existing literature on alopecia areata (AA) clearly demonstrates patients' concerns related to physical symptoms, emotional well-being, mental health, social functioning, and other dimensions of daily functioning. Although questionnaires such as the Skindex-16 and the Dermatology Life Quality Index have been used, these questionnaires were validated for skin conditions other than AA as a chronic condition. The goals of this study are to develop a measure of quality of life, symptoms, and their impact for patients with AA called the Alopecia Areata Symptom Impact Scale (AASIS) and to provide psychometric evidence for its use. We used data from 1,400 patients from the National Alopecia Areata Registry together with clinical experts' reviews and quantitative approaches. The preliminary version of the AASIS with 13 items was administered to about 210 patients with AA. Results indicated that the AASIS measures three underlying constructs related to AA. These dimensions were impact of AA, hair loss, and physical skin symptoms. The internal consistency reliabilities of these subscales are 0.93, 0.86, and 0.81, respectively. Cognitive debriefing results showed that patients find the AASIS items easy to understand, clear, and concise. Preliminary evidence suggests that the AASIS is a reliable and valid measure of the symptoms and their impact in patients with AA.